HC Wainwright Has Weak Forecast for Gossamer Bio Q2 Earnings

Posted by Brenda Bartman on May 28th, 2026

Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings estimates for Gossamer Bio in a note issued to investors on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.09) for the quarter, down from their prior estimate of ($0.05). HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.42) EPS, Q3 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.20) EPS.

A number of other equities analysts have also issued reports on GOSS. The Goldman Sachs Group lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Royal Bank Of Canada upgraded shares of Gossamer Bio to an “outperform” rating in a research report on Tuesday, February 24th. Cantor Fitzgerald restated a “neutral” rating on shares of Gossamer Bio in a research report on Monday, March 23rd. Wedbush restated a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday, February 24th. Finally, Leerink Partners lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Four research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.00.

Check Out Our Latest Research Report on Gossamer Bio

Gossamer Bio Trading Down 1.0%

Shares of GOSS opened at $0.22 on Thursday. The firm has a market cap of $51.14 million, a PE ratio of -0.28 and a beta of 2.15. The company’s 50 day simple moving average is $0.35 and its 200-day simple moving average is $1.71. Gossamer Bio has a 12-month low of $0.16 and a 12-month high of $3.87.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last announced its earnings results on Monday, May 18th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $16.96 million for the quarter, compared to analyst estimates of $4.67 million.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of GOSS. Legal & General Group Plc purchased a new position in Gossamer Bio in the 2nd quarter valued at $26,000. Banco BTG Pactual S.A. purchased a new position in Gossamer Bio in the 2nd quarter valued at $27,000. MMA Asset Management LLC purchased a new position in Gossamer Bio in the 4th quarter valued at $31,000. Soltis Investment Advisors LLC purchased a new position in Gossamer Bio in the 4th quarter valued at $31,000. Finally, Beacon Pointe Advisors LLC purchased a new position in Gossamer Bio in the 4th quarter valued at $34,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio News Roundup

Here are the key news stories impacting Gossamer Bio this week:

Positive Sentiment: HC Wainwright reaffirmed its Buy rating on Gossamer Bio and maintained a $5.00 price target, indicating meaningful upside relative to the current share price. Benzinga article
Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Berger Montague, the Schall Law Firm, Pomerantz, and others, issued reminders about the June 1, 2026 lead plaintiff deadline for the class action lawsuit covering investors who bought shares between June 16, 2025 and February 20, 2026. These notices keep the litigation story in focus. Berger Montague reminder article
Neutral Sentiment: Additional “deadline alert” announcements from other firms are largely procedural and mostly reinforce that shareholder litigation is ongoing rather than adding new operational news. Frank R. Cruz deadline alert article
Negative Sentiment: The core lawsuit centers on allegations that Gossamer’s executives concealed risks tied to the PROSERA trial outcome, including the study failing to meet its primary endpoint. That kind of clinical setback can raise concerns about future pipeline value and prolong uncertainty for shareholders. HBSS article

About Gossamer Bio

(Get Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.